CTOs on the Move

Agility Health

www.agilityhealth.com

 
Agility Health is a leading healthcare provider devoted to the rehabilitation of our patients' physical injuries and conditions. Established in 1968, Agility Health delivers personalized care through over one million therapy visits annually at more than 155 service sites in 20 states nationwide. Our team is dedicated to providing exceptional value to the patients, clients and partners we serve. Through our innovative clinical services, proven practice management systems and flexible partnerships, we help achieve optimal performance in a variety of settings, including outpatient clinics, hospitals, long-term care facilities and employer work sites. Agility Health is one of the top 10 rehabilitation services ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Minnetronix

Minnetronix is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MedPoint Digital

MedPoint is focused on innovative, high-value services. We are a global best-in-class company in our service areas. We work with clients on new approaches to training, education and communications that work in the real world of medicine.

Diamond Recovery Centers

Diamond Recovery Centers is run by members in recovery, industry-leading professionals, and world-class clinicians. Our mission statement is ” If we put the clients and their needs first, everything else will fall in place”. Our only goal is to help those struggling with Mental Health and Substance Abuse one client at a time.

BDC Advisors

BDC Advisors is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

T3D Therapeutics

T3D Therapeutics` mission is to develop its lead drug product candidate, T3D-959, as a potential `First-in-Class`and `Best-in-Class` disease-modifying, breakthrough medicine for the treatment of Alzheimer`s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D=959 and has initiated pre-clinical studies in Huntington’s Disease models.